Searching for targets for the systemic therapy of mesothelioma.

Details

Ressource 1Download: serval:BIB_927822C7CC73.P001 (282.43 [Ko])
State: Public
Version: author
License: Not specified
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
Serval ID
serval:BIB_927822C7CC73
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Searching for targets for the systemic therapy of mesothelioma.
Journal
Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo
Author(s)
Stahel R.A., Weder W., Felley-Bosco E., Petrausch U., Curioni-Fontecedro A., Schmitt-Opitz I., Peters S.
ISSN
1569-8041 (Electronic)
ISSN-L
0923-7534
Publication state
Published
Issued date
2015
Peer-reviewed
Oui
Volume
26
Number
8
Pages
1649-1660
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review
Publication Status: ppublish
Abstract
Malignant mesothelioma is an incurable disease associated with asbestos exposure arising in the pleural cavity and less frequently in the peritoneal cavity. Platinum-based combination chemotherapy with pemetrexed is the established standard of care. Multimodality approaches including surgery and radiotherapy are being investigated. Increasing knowledge about the molecular characteristics of mesothelioma had led to the identification of novel potential targets for systemic therapy. Current evidence suggests pathways activated in response to merlin deficiency, including Pi3K/mTOR and the focal adhesion kinase, as well as immunotherapeutic approaches to be most promising. This review elaborates on the rationale behind targeted approaches that have been and are undergoing exploration in mesothelioma and summarizes available clinical results and ongoing efforts to improve the systemic therapy of mesothelioma.
Keywords
Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Cisplatin/administration & dosage, Everolimus/administration & dosage, Focal Adhesion Protein-Tyrosine Kinases/antagonists & inhibitors, Focal Adhesion Protein-Tyrosine Kinases/metabolism, Humans, Immunotherapy, Lung Neoplasms/drug therapy, Lung Neoplasms/metabolism, Mesothelioma/drug therapy, Mesothelioma/metabolism, Molecular Targeted Therapy/methods, Pemetrexed/administration & dosage, Phosphatidylinositol 3-Kinases/antagonists & inhibitors, Phosphatidylinositol 3-Kinases/metabolism, Pleural Neoplasms/drug therapy, Pleural Neoplasms/metabolism, Protein Kinase Inhibitors/administration & dosage, TOR Serine-Threonine Kinases/antagonists & inhibitors, TOR Serine-Threonine Kinases/metabolism
Pubmed
Web of science
Open Access
Yes
Create date
07/09/2015 15:48
Last modification date
25/09/2019 7:10
Usage data